Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib for refractory Cushing's disease
ChiCTR-OPC-17011664Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lapatinib in Corticotropin adenoma (ACTHoma) and pituitary adenoma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Serum ACTH level. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
lapatinib
03
Conditions
Corticotropin adenoma (ACTHoma)pituitary adenoma
Beyond the preview
Go deeper on ChiCTR-OPC-17011664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011664.